Monitor the WCLC conference (Sept 12-15, 2026) for actual clinical data readouts on pumitamig, gotistobart, and the pumitamig+elfetabart drozuntecan combination. The stock may move on data quality, but this filing itself is a routine pipeline update with no immediate catalyst.
Price Chart
Executive Summary
BioNTech filed a 6-K press release announcing upcoming data presentations at the IASLC 2026 World Conference on Lung Cancer (WCLC), including first global data for the novel-novel combination of pumitamig plus elfetabart drozuntecan and updated overall survival data for gotistobart from the PRESERVE-003 Phase 3 trial. The filing is a routine pipeline update with no financial data, and the actual clinical results will not be disclosed until the conference in September 2026, limiting near-term trading impact.
Key Facts
- BioNTech will present data at WCLC 2026 (Sept 12-15) from its lung cancer pipeline, including first data for pumitamig + elfetabart drozuntecan combination and updated OS for gotistobart.
- The filing is a curtain-raiser press release with no clinical results disclosed; actual data will be presented at the conference.
- BioNTech has 16 ongoing lung cancer trials, including five Phase 3 and two novel-novel combination trials.
- No financial figures, guidance, or material agreements were included in this filing.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- Clinical trial data may fail to meet expectations, leading to negative stock reaction at WCLC.
- Forward-looking statements about pipeline progress are subject to regulatory and development risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000057 |
| Document: form6-kwclccurtainraiser20.htm | 0001776985-26-000057 |
| Document: 0001776985-26-000057-index-headers.html | 0001776985-26-000057 |
| Document: 0001776985-26-000057-index.html | 0001776985-26-000057 |
| Document: 0001776985-26-000057.txt | 0001776985-26-000057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access